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Background: As disseminated intravascular coagulation (DIC) causes multiple organ failure, recombinant
thrombomodulin (rTM) is widely used in Japan for treating DIC. However, the optimal timing of rTM administration has
not yet been determined. We hypothesized that the administration of rTM before progression of disease causing DIC
might be better for the treatment of DIC than that after progression of disease.
Methods: A total of 101 patients received rTM in the intensive care unit (ICU) between August 2008 and November
2013 were enrolled. Depending on survival at hospital discharge, the patients were divided into survivor (group S) and
non-survivor groups (group NS). Patient characteristics before DIC development, acute physiology and chronic health
evaluation II (APACHEII) score and sequential organ failure assessment (SOFA) score at the start of rTM administration,
rTM administration dose, duration of time between the onset of disease causing DIC and rTM administration, and
combination therapy were collected.
Results: Group S had 57 patients, and group NS had 44 patients. More than 70% of patients in group S were
administrated rTM within 1 day from the onset of disease causing DIC (0 days, 40% vs 20%; 1 day, 33% vs 30%;
more than 2 days, 26% vs 50%). At the start of the rTM administration, the APACHEII and SOFA scores were
significantly lower in group S (26 ± 6 vs 32 ± 6, p < 0. 001; 9.5 ± 4.2 vs 13.4 ± 3.6, p < 0.001). Multivariate logistic
regression analysis of outcomes was performed. The duration of time between the onset of disease causing DIC
and rTM administration, the APACHEII score, the SOFA score, and use of continuous renal replacement therapy
(CRRT) were selected as candidate variables (p < 0.05). The SOFA scores and use of CRRT were highly correlated
with the APACHEII score (Pearson correlation = 0.63 and 0.43, respectively). Therefore, the SOFA score and the use
of CRRT were excluded from this model. Late administration of rTM (more than 2 days between the onset of
disease and rTM administration) was associated with undesirable outcome (odds ratio = 3.36, 95% confidence
interval = 1.03–10.92, p = 0.044).
Conclusions: This study suggested that the administration of rTM before the progression of disease causing DIC
might be better than that after progression of disease causing DIC. Further randomized clinical trials are required
to elucidate whether early administration of rTM is actually effective.
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Figure 1 Disseminated Intravascular Coagulation scoring
system. Disseminated Intravascular Coagulation scoring system was
shown. SIRS items of the diagnostic criteria of systemic inflammatory
response syndrome are satisfied, PT ratio prothrombin time ratio,
FDP concentration of fibrin/fibrinogen degradation products.
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Disseminated intravascular coagulation (DIC) occurs in
9%–19% of patients in the intensive care unit (ICU), and
rate of mortality associated with DIC is as high as 45%–
78% [1]. The development of new therapies to treat DIC
is expected because this rate has not changed in the last
10 years [1]. In Japan, recombinant human soluble
thrombomodulin-alpha (rTM) (Recomodulin, Asahi Kasei
Pharma, Tokyo, Japan) has been available as a therapeutic
DIC drug since 2008. This drug binds to thrombin to in-
activate coagulation [2]. In addition, rTM promotes pro-
tein C activation by thrombin, resulting in the formation
of activated protein C (APC) [2]. APC in turn inhibits
thrombin generation by inactivating coagulation factors
Va and VIIIa to inhibit the activation of the blood coagula-
tion system [2]. In our ICU, rTM has been used as the
first-line drug for the treatment of DIC because it is more
effective than heparin and has fewer bleeding-related side
effects [2]. Recently, the safe use of rTM for ICU patients
has been reported in a phase IIb study of rTM [3]. An-
other study had shown that rTM may be superior to con-
ventional DIC treatments in patients in the ICU [4].
However, the optimal timing of rTM administration has
not yet been determined. We hypothesized that the ad-
ministration of rTM before the progression of disease
causing DIC might be better for the treatment of DIC
than that after progression of disease causing DIC. There-
fore, we investigated whether the timing of rTM adminis-
tration was associated with differences between survivors
and non-survivors in a retrospective analysis.
Methods
Ethics statement
This study was approved by the ethics committee of
Kochi Medical School, and the need to obtain informed
consent was waived because this study was a retrospect-
ive analysis. In our hospital, every patient was able to de-
clare refusing use of data from the present to the future
in writing. Therefore, patients who refused the use of
their record were excluded from the study.
Patients
The subjects included a consecutive series of patients
with DIC who were treated with rTM in our ICU be-
tween August 2008 and November 2013. Of these pa-
tients, those <18 years of age and those who refused the
use of their record at hospitalization were excluded from
the study. Depending on survival at hospital discharge,
the patients were divided into survivor (group S) and
non-survivor groups (group NS).
Diagnosis of DIC
The diagnosis of DIC was based on the DIC criteria of
the Japanese Association for Acute Medicine [5]. Thesediagnostic criteria consist of four items, namely, more
than three items of the diagnostic criteria of systemic in-
flammatory response syndrome are satisfied, the platelet
count, the prothrombin time ratio, and the concentra-
tion of fibrin/fibrinogen degradation products (Figure 1).
Patients with a total score of ≥4 were diagnosed as hav-
ing DIC.
The onset of disease causing DIC
We defined the onset of disease causing DIC as the tim-
ing when individual physicians diagnosed it and wrote
medical records.
Treatment
According to the drug information, the doses of rTM
are defined as 380 and 130 U/kg/day for patients with
non-impaired renal function and those with impaired
renal function, respectively. However, the drug informa-
tion does not define impaired renal function and recom-
mends decrease to 130 U/kg/day if bleeding occurs in
patients with impaired renal function. Therefore, indi-
vidual physicians decided the doses of rTM in accord-
ance with this recommendation and patient status. In
addition, sepsis was treated in accordance with the Sur-
viving Sepsis Campaign Guidelines [6,7], but the details
were decided by individual physicians.
Data collection
The following data were obtained from electronic pa-
tient records: patient characteristics before DIC develop-
ment, acute physiology and chronic health evaluation II
(APACHEII) score and sequential organ failure assess-
ment (SOFA) score at the start of rTM administration,
rTM administration dose and duration, duration of time







Age, years, mean ± SD 68 ± 17 75 ± 11 0.036
Height, cm, mean ± SD 157 ± 8 157 ± 8 0.71
Weight, kg, mean ± SD 49 ± 10 58 ± 12 <0.001
BMI, kg/m2, mean ± SD 20 ± 4 23 ± 4 <0.001
Gender, female, n 27 10 0.011
Infection-induced DIC, n 48 38 0.76
Intra-abdominal, n 29 24
Lung, n 9 10
Urinary, n 3 0
Others, n 7 4
Non-infection-induced DIC, n 9 6 0.34
Obstetric, n 2 0
Intestinal ischemia, n 2 3
Others, n 5 3
Heart disease, n 12 15 0.14
Diabetes mellitus, n 15 16 0.27
Hypertension, n 30 22 0.79
Smoking, n 19 22 0.091
BMI body mass index, DIC disseminated intravascular coagulation.
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ministration, and combination therapy.
Statistical analysis
Data are expressed as the mean ± standard deviation. As-
sociations between the outcome and baseline variables
were examined by univariate analysis. For the analysis of
continuous variables, a t test was used, and a chi-square
test was used to analyze categorical variables. Variables
were considered potentially associated with outcome when
p < 0.05; these variables were further evaluated using a
multivariate logistic regression model. The age was in-
cluded in components of the APACHEII score. Therefore,
it was excluded from this model. When the linearity as-
sumptions considered were violated, continuous variables
were divided into tertiles and analyzed as discrete variables.
For all analyses, a two-sided p value <0.05 was considered
statistically significant. Favorableness of fit was evaluated
using the Hosmer-Lemeshow test, and predictive ability
was confirmed by c-statistics based on receiver operating
characteristic analysis. Statistical analysis was performed
using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 105 patients received rTM in the ICU. Of these
patients, 101 were analyzed; three patients <18 years of
age and one patient who refused the use of his record
were excluded from the study. Groups S and NS included
57 and 44 patients, respectively. Of the patient character-
istics before the onset of DIC, data on heart disease, dia-
betes, hypertension, and the rate of smokers did not
significantly differ between the groups (Table 1). However,
the group NS had fewer women (47% vs 22%, p = 0.011)
and a higher average BMI (20 ± 4 vs 23 ± 4, p < 0.001) than
the group S. The age in group NS was higher than that in
group S (68 ± 17 vs 75 ± 11, p = 0.036).
The relationship between DIC and administration of rTM
The duration from the onset of disease causing DIC to
rTM administration in group S and NS is shown in
Table 2 (0 days, 40% vs 20%; 1 day, 33% vs 30%; more
than 2 days, 26% vs 50%). More than 70% of the patients
in group S were administrated rTM within 1 day from
the onset of disease causing DIC. Administration of
rTM in group S was significantly earlier from the onset
of disease causing DIC (p = 0.030). The relationship of
time duration between the onset of disease and rTM ad-
ministration (as X factor) with survival rate (as Y factor)
is shown in Figure 2.
Severity of illness and treatment for DIC
At the start of rTM administration, the APACHEII and
SOFA scores were significantly lower in group S asshown in Table 2 (26 ± 6 vs 32 ± 6, p < 0. 001; 9.5 ± 4.2 vs
13.4 ± 3.6, p < 0.001). Although the DIC scores at the
start of rTM administration were not significantly differ-
ent in both groups, the DIC score at the end of rTM ad-
ministration in group S was significantly lower than that
in group NS. The use of continuous renal replacement
therapy (CRRT) was significantly higher in group NS
(58% vs 91%, p < 0.001). The rate of mechanical ventila-
tion with intratracheal intubation in group NS was sig-
nificantly higher than that in group S. The duration of
mechanical ventilation with intratracheal intubation was
significantly shorter in group S (11 ± 17 vs 23 ± 38 days,
p = 0.038).
Hemorrhagic complications
Hemorrhagic complications occurred in two patients
(2.0%). Of the two patients, one who received rTM com-
bined with gabexate mesilate for 2 days developed bleed-
ing of the ocular fundus. Another patient with cirrhosis
(Child-Pugh classification B) developed a respiratory tract
hemorrhage. Multivariate logistic regression analysis of
outcomes was performed (Table 3).
Multivariate logistic regression analysis for outcome
The duration of time between the onset of disease caus-
ing DIC and rTM administration, the APACHEII score,
the SOFA score, and CRRT use were selected as







rTM treatment duration, days, mean ± SD 6.1 ± 2.9 6.4 ± 8.4 0.78
Dose of rTM, U/kg/day, mean ± SD 345 ± 108 308 ± 100 0.083
Duration from onset to rTM, n (%) 0.030
0 days 23 (40) 9 (20)
1 day 19 (33) 13 (30)
2 days 15 (26) 22 (50)
APACHEII at start of rTM, mean ± SD 26 ± 6 32 ± 6 <0.001
SOFA at start of rTM, mean ± SD 9.5 ± 4.2 13.4 ± 3.6 <0.001
DIC score at start of rTM, mean ± SD 5.2 ± 1.8 5.6 ± 1.7 0.20
DIC score at end of rTM, mean ± SD 3.0 ± 2.0 4.9 ± 1.9 <0.001
Ventilation with tracheal intubation, n (%) 47 (82) 43 (98) 0.01
Duration of ventilation, days, mean ± SD 11 ± 17 23 ± 38 0.038
CRRT during rTM therapy, n 33 40 <0.001
Antithrombin-III during rTM therapy, n 36 30 0.60
Globulin during rTM therapy, n 26 21 0.83
Transfusion during rTM therapy, n 43 37 0.29
Enteral nutrition during rTM therapy, n 34 18 0.11
rTM recombinant thrombomodulin, U unit, Duration from onset to rTM duration
from the onset of disease causing DIC to rTM administration, APACHEII Acute
Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure
Assessment scores, at start of rTM at the start of rTM administration, at end of rTM
at the end of rTM administration, DIC score score of DIC criteria of the Japanese
Association for Acute Medicine, CRRT continuous renal replacement therapy.
Figure 2 The relationship of time duration between the onset
of disease and recombinant thrombomodulin administration
with survival rate. The relationship of time duration between the
onset of disease and recombinant thrombomodulin (rTM) administration
(as X factor) with survival rate (as Y factor). Gray bar denotes mean
survival rate, and gray line signifies mean 95% confidence interval.







Gender Female 3.39 1.19–9.64 0.022
APACHEII at
start of rTM
- 1.18 1.09–1.29 <0.001
rTM 1 day 0 days 1.95 0.57–6.62 0.29
rTM 2 days 0 days 3.36 1.03–10.92 0.044
Hosmer-Lemeshow test (chi-square = 15.13, degrees of freedom = 8, p = 0.057).
C-statistics = 0.82.
APACHEII Acute Physiology and Chronic Health Evaluation II, rTM recombinant
thrombomodulin. rTM x day Duration from the onset of disease to rTM
administration was x day, 2- days more than 2 days.
Yatabe et al. Journal of Intensive Care 2014, 2:49 Page 4 of 6
http://www.jintensivecare.com/content/2/1/49candidate variables (p < 0.05). The SOFA scores and
CRRT use were highly correlated with the APACHEII
score (Pearson correlation = 0.63 and 0.43, respectively).
Therefore, the SOFA score and the use of CRRT were
excluded from this model. Late administration of rTM
(more than 2 days between the onset of disease and rTM
administration) was associated with undesirable outcome
(odds ratio = 3.36, 95% confidence interval = 1.03–10.92,
p = 0.044).
Discussion
Patients who would benefit from rTM remained unclear.
However, the results of this study indicated that the ad-
ministration of rTM before an increase in the severity of
disease causing DIC might be better than that after pro-
gression of disease causing DIC if we select rTM for the
treatment of DIC. Therefore, we should consider admin-
istration of rTM as soon as possible after we diagnose
severe diseases with DIC such as sepsis. As clearly
shown in this study, the treatment of rTM might not be
effective after diseases have progressed and the severity
of the patients’ conditions, based on the APACHEII and
SOFA scores, has increased. Late administration of rTM
(more than 2 days from the onset of disease to rTM ad-
ministration) was associated with a threefold higher risk
of undesirable outcomes than early administration.
These data suggested that administration of rTM before
progression of disease causing DIC might be better than
that after progression of disease. The correlation be-
tween rTM administration timing and the prognosis of
patients with rTM has not been reported. On the other
hand, previous reports indicated that APC administra-
tion in the advanced phase, for example, in patients with
high APACHE II scores (more than 25), was effective,
but early administration of APC was not effective [8,9].
We did not compare between these studies about APC
and our study because the APACHE II scores in our
study were more than 25. In addition, cases in which
early administration of rTM was possible, such as delay
of diagnosis of DIC, might exist in our study because of
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could not deny that the diagnosis of DIC might be delayed
in general ward because the prothrombin time ratio and
the concentration of fibrin/fibrinogen degradation prod-
ucts were not usually measured. In these cases, we might
diagnose DIC after ICU admission, although DIC had
already occurred before ICU admission. However, we
thought that the results of the correlation between rTM
administration timing and the prognosis of patients with
rTM did not change. Therefore, further randomized clin-
ical trials are required to elucidate whether early adminis-
tration of rTM is actually effective.
This drug exerts effect of anticoagulation via unique
mechanism. The use of rTM promotes protein C activation
by thrombin, resulting in the inhibition of thrombin gener-
ation, namely, a negative feedback loop [10]. This mechan-
ism might contribute to few hemorrhagic complications.
Indeed, a previous study reported that hemorrhagic com-
plications occurred in 8.6% of patients who received APC
[11]. On the other hand, hemorrhagic complications in our
study were observed in two patients, but the frequency was
as low as 2.0%. One patient who developed bleeding of
the ocular fundus improved completely without any
medication. Another patient with cirrhosis stopped having
a respiratory tract hemorrhage after platelet transfusion
because of low platelet count due to DIC and cirrhosis.
These patients such as those having serious liver damage
and those who use anticoagulation drug might require fur-
ther attention. Further examination is necessary because
this study included only two such patients.
This study has several limitations because of its retro-
spective design. First, we could not determine the effect
of rTM itself because this study did not include a con-
trol group in which rTM was not administered, since
rTM is the first-line drug for the treatment of DIC in
our hospital. At least, the mortality rate in this study
was 44%, which is equivalent to or better than those re-
ported in earlier studies [1]. In addition, this study sug-
gested that administration of rTM after progression of
disease causing DIC might be less effective. Therefore,
the independent effect of rTM compared with other
treatments in the early phase of DIC needs to be eluci-
dated in other studies. Second, the therapeutic method
was decided by individual physicians. Therefore, the use
of CRRT was significantly different. Although many pa-
tients in group NS received CRRT, whether death was
due to the severity of the underlying disease or whether
the results were biased is unclear. In addition, the APA-
CHE II score in group NS was significantly higher than
that in group S. However, we performed multivariate lo-
gistic regression analysis. At least, we believed that in
our study, late administration of rTM tended to be asso-
ciated with increased mortality. Third, group S had more
number of female patients. Sepsis-related mortality ratesare reported to be higher in female patients than in male
patients [1]. Although gender was highly associated with
the outcomes in our multivariate logistic regression ana-
lysis, the late administration of rTM was also a risk fac-
tor for mortality. The c-statistics in this model was
0.820, which suggests that the results of this analysis are
reliable. Finally, the age in group NS was higher than
that in group S. However, age was included in the com-
ponents of the APACHEII score. Therefore, age was
correlated with the APACHEII score (Pearson correl-
ation = 0.29). In this reason, age was excluded from this
model.
Conclusions
In conclusion, the results of this study suggest that ad-
ministration of rTM before progression of disease caus-
ing DIC might be better for the treatment of DIC than
that after progression of disease causing DIC because
DIC scores at the start of rTM were not significantly dif-
ferent between groups S and NS. In other words, admin-
istration of rTM after progression of disease might be
less effective. However, this study was a retrospective
study and did not have a control group. Therefore, fur-
ther randomized clinical trials are required to elucidate
whether early administration of rTM is actually effective.
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